Literature DB >> 19406204

Role of TRPV1 in high-threshold rat colonic splanchnic afferents is revealed by inflammation.

Benjamin D Phillis1, Chris M Martin, Daiwu Kang, Håkan Larsson, Erik A Lindström, Vicente Martinez, L Ashley Blackshaw.   

Abstract

The vanilloid-1 receptor TRPV1 is known to play a role in extrinsic gastrointestinal afferent function. We investigated the role of TRPV1 in mechanosensitivity in afferents from normal and inflamed tissue. Colonic mechanosensitivity was determined in an in vitro rat colon preparation by recording from attached splanchnic nerves. Recordings were made from serosal/mesenteric afferents responding only at high thresholds to graded mechanical stimulation with von Frey probes. Colonic inflammation was induced by adding 5% dextran sulphate sodium (DSS) to the drinking water for 5 days, and was confirmed by histopathology. The selective TRPV1 antagonist, SB-750364 (10(-8) to 10(-6)M), was tested on mechanosensory stimulus response functions of afferents from normal and inflamed preparations (N=7 each). Mechanosensory responses had thresholds of 1-2g, and maximal responses were observed at 12 g. The stimulus response function was not affected by DSS-induced colitis. SB-750364 had no effect on stimulus response functions in normal preparations, but reduced (up to 60%) in a concentration-dependent manner those in inflammation (2-way ANOVA, p<0.05). Moreover, in inflamed tissue, spontaneous afferent activity showed a dose-dependent trend toward reduction with SB-750364. We conclude that mechanosensitivity of high-threshold serosal colonic splanchnic afferents to graded stimuli is unaffected during DSS colitis. However, there is a positive influence of TRPV1 in mechanosensitivity in inflammation, suggesting up-regulation of excitatory TRPV1-mediated mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406204     DOI: 10.1016/j.neulet.2009.04.051

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

Review 2.  TRPA1: A gatekeeper for inflammation.

Authors:  Diana M Bautista; Maurizio Pellegrino; Makoto Tsunozaki
Journal:  Annu Rev Physiol       Date:  2012-09-27       Impact factor: 19.318

Review 3.  TRP channels in neurogastroenterology: opportunities for therapeutic intervention.

Authors:  Werend Boesmans; Grzegorz Owsianik; Jan Tack; Thomas Voets; Pieter Vanden Berghe
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Combined genetic and pharmacological inhibition of TRPV1 and P2X3 attenuates colorectal hypersensitivity and afferent sensitization.

Authors:  Michael E Kiyatkin; Bin Feng; Erica S Schwartz; G F Gebhart
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-08-29       Impact factor: 4.052

Review 5.  TRP channel functions in the gastrointestinal tract.

Authors:  Xiaoyun Yu; Mingran Yu; Yingzhe Liu; Shaoyong Yu
Journal:  Semin Immunopathol       Date:  2015-10-12       Impact factor: 9.623

6.  TRPM8 on mucosal sensory nerves regulates colitogenic responses by innate immune cells via CGRP.

Authors:  P R de Jong; N Takahashi; M Peiris; S Bertin; J Lee; M G Gareau; A Paniagua; A R Harris; D S Herdman; M Corr; L A Blackshaw; E Raz
Journal:  Mucosal Immunol       Date:  2014-10-01       Impact factor: 7.313

7.  Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1.

Authors:  QiQi Zhou; Liuqing Yang; Scott Larson; Sapreet Basra; Shehzad Merwat; Alai Tan; Carlo Croce; G Nicholas Verne
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

Review 8.  Transient Receptor Potential Channels and Inflammatory Bowel Disease.

Authors:  Yiding Chen; Jingxi Mu; Min Zhu; Arjudeb Mukherjee; Hu Zhang
Journal:  Front Immunol       Date:  2020-02-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.